The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000531314p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
7/04/2026
Date registered
Help: Date registered
29/04/2026
Date last updated
Help: Date last updated
21/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
29/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Ear Nose Throat (ENT) Probiotic Trial in Adults with Acute Streptococcal Pharyngitis/Tonsillitis
Scientific title
Randomized, double-blind, placebo-controlled trial evaluating the effectiveness of a probiotic formula in adults with acute streptococcal Pharyngitis and/or Tonsillitis.
Additional trial identifiers [1] 316965 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Streptococcal pharyngitis 341421 0
Tonsilitis 341422 0
Condition category
Condition code
Infection 337477 337477 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The parallel, dual-centre, randomised, double-blind, placebo-controlled, intervention trial will examine the effect of a probiotic formula on acute symptomatic streptococcal pharyngitis and/or tonsilitis.
Participants will be randomised into either placebo or probiotic arms. The probiotic formula is registered with the Therapeutic Goods Administration (TGA) and is packaged in sachets. Each sachet contains four live probiotic cultures together with excipient ingredients. The placebo contains only excipient ingredients. Participants will consume one sachet daily for six weeks at night before bed. Each sachet is designed for oral administration and to be taken without food or water. Participants will allow the powder to dissolve and coat the inside of the mouth. Any antibiotics will be taken at least two hours before sachet intake. Adherence will be monitored using daily symptom and adherence diaries and returned sachet counts at the 6-week follow-up visit.
Throughout the intervention period, participants will be asked to complete a daily symptom and adherence diary to capture symptom presence, severity, healthcare use, antibiotic use and study product intake. Participants will also be asked to complete a validated questionnaire once a week to assess gastrointestinal symptom severity.
Participants will be asked to attend two study visits (week 0 and week 6) at the Food, Nutrition and Dietetics Laboratory at La Trobe University, Bundoora Campus. A trained researcher will conduct a clinical assessment using the Modified Centor (McIsaac) Score, a throat swab for Streptococcus pyogenes culture and a saliva sample for assessing oral microbiota composition. Early-morning venous blood samples will be drawn by a trained researcher or qualified phlebotomist. Self-reported questionnaires and diaries regarding gastrointestinal symptom severity, health-related quality of life, global improvement, food intake and physical activity will be completed. Anthropometric and body composition data will be obtained.
Intervention code [1] 333695 0
Treatment: Other
Description of the comparator or control
Participants in the placebo group will receive sachets containing only excipient ingredients.
Control group
Placebo

Outcomes
Primary outcome [1] 344987 0
Total number of symptomatic days
Timepoint [1] 344987 0
Daily from baseline (week 0) to follow-up (week 6, primary timepoint)
Secondary outcome [1] 460045 0
Symptom severity
Timepoint [1] 460045 0
Daily from baseline (week 0) to follow-up (week 6)
Secondary outcome [2] 460046 0
Recurrence of pharyngitis/tonsillitis episodes
Timepoint [2] 460046 0
Daily from baseline (week 0) to follow-up (week 6)
Secondary outcome [3] 460047 0
Antibiotic use
Timepoint [3] 460047 0
Daily from baseline (week 0) to follow-up (week 6)
Secondary outcome [4] 460048 0
Health-related quality of life
Timepoint [4] 460048 0
Baseline (week 0) and follow-up (week 6)
Secondary outcome [5] 460049 0
Presence of Streptococcus pyogenes
Timepoint [5] 460049 0
Baseline (week 0) and follow-up (week 6)
Secondary outcome [6] 460050 0
Changes in oral microbiota composition
Timepoint [6] 460050 0
Baseline (week 0) and follow-up (week 6)
Secondary outcome [7] 460514 0
Gastrointestinal symptoms
Timepoint [7] 460514 0
Weekly from baseline (week 0) to follow-up (week 6)
Secondary outcome [8] 460521 0
High-sensitivity C-reactive protein (hs-CRP)
Timepoint [8] 460521 0
Baseline (week 0) and follow-up (week 6)
Secondary outcome [9] 460522 0
Interleukin 6 (IL-6)
Timepoint [9] 460522 0
Baseline (week 0) and follow-up (week 6)
Secondary outcome [10] 460524 0
Safety and tolerability (composite outcome)
Timepoint [10] 460524 0
Daily from baseline (week 0) to follow-up (week 6)

Eligibility
Key inclusion criteria
• Recently identified in routine care as having acute symptomatic streptococcal pharyngitis and/or tonsillitis within 72 hours prior to enrolment, with eligibility confirmed by the study team based on clinical documentation and/or GP verification consistent with local clinical practice (including availability of recent throat swab/culture where applicable).
• Able and willing to provide written informed consent.
• Willing and able to comply with study procedures, including daily symptom reporting and attendance at baseline and Week 6 visits.
• For the Melbourne site, able to read and understand English sufficiently to complete study materials.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Known or suspected immunodeficiency, or current use of immunosuppressive therapy.
• Antibiotic use within 14 days prior to baseline enrolment.
• Use of probiotics or yeast-based supplements (including Saccharomyces-supplemented products) within the past month.
• Current pregnancy or breastfeeding (or planning pregnancy during the intervention period).
• Known allergy or hypersensitivity to Saccharomyces boulardii, isomalt, or any product excipients.
• Severe or uncontrolled chronic medical condition(s) that, in the opinion of the investigators, may confound symptom reporting, compromise participant safety, or interfere with adherence.
• Current participation in another interventional clinical trial.
• Any condition or circumstance that would limit the participant’s ability to complete study procedures (e.g., inability to attend visits, inability to complete diaries) or provide valid consent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
An independent researcher, not involved in the trial, will determine group assignment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation (1:1) using a computer-generated 6-block randomisation list
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The sample size was determined to ensure adequate statistical power to detect a clinically meaningful difference between the intervention and placebo groups for the primary outcome, defined as the total number of symptomatic days over the 6-week intervention period.
Based on prior probiotic trials in upper respiratory and oropharyngeal conditions and the absence of directly comparable data for tested probiotic strains in this population, a moderate standardised effect size (Cohen’s d = 0.5) was prespecified as both clinically relevant and conservative. Sample size calculations assumed a two-sided significance level (a) of 0.05 and 80% statistical power (1 - ß = 0.80).
Power calculations were performed using G*Power version 3.1.9.7, assuming a between-group comparison of a continuous outcome, consistent with the planned primary analysis using analysis of covariance (ANCOVA) and linear mixed-effects modelling adjusting for baseline symptom severity.
Under these assumptions, a minimum of 90 evaluable participants (45 per group) would be required to detect a between-group difference corresponding to Cohen’s d = 0.5. To account for an anticipated attrition rate of up to 30% (due to withdrawal, loss to follow-up, or incomplete diary data), the target sample size was inflated accordingly.
The final planned sample size is therefore N = 128 participants (64 per group).
As the study will be conducted across two sites (Melbourne, Australia, and Athens, Greece), recruitment will be approximately equally distributed between sites (64 participants per site) to support balanced allocation and enable exploratory analyses of site-level effects. The study is not powered for formal site-by-treatment interaction testing; such analyses will be considered exploratory.
This sample size is expected to provide sufficient power for the primary outcome analysis under an intention-to-treat framework, while also allowing for robust secondary, exploratory, and sensitivity analyses, including per-protocol analyses among participants with =80% adherence.

The primary analysis will compare the total number of symptomatic days over the 6-week intervention period between intervention and placebo groups using analysis of covariance (ANCOVA), adjusting for baseline symptom severity and study site.
Secondary outcomes (e.g. symptom severity trajectories, quality of life, antibiotic use, recurrence) will be analysed using linear mixed-effects models or appropriate generalised models to account for repeated measures and non-normal outcome distributions. Categorical outcomes (e.g. antibiotic use, recurrence) will be analysed using logistic regression or chi-square tests, as appropriate.
Microbiota data will be analysed using standard bioinformatics pipelines, including alpha- and beta-diversity metrics, differential abundance testing (e.g. DESeq2), and exploratory correlations with clinical outcomes. Inflammatory biomarkers (hs-CRP, IL-6) will be analysed using parametric or non-parametric methods depending on distribution, with transformation applied where required.
Primary analyses will follow the intention-to-treat (ITT) principle. Per-protocol analyses will be conducted as sensitivity analyses among participants with =80% adherence. Missing data will be handled using multiple imputation under a missing-at-random assumption, with additional sensitivity analyses performed to assess robustness.

Recruitment
Recruitment status
Withdrawn
Reason for early stopping/withdrawal
Other reasons/comments
Other reasons
Trial cancelled and abandoned prior to implementation as extensive modifications have resulted in significant divergence, rendering the registered ANZCTR protocol invalid.
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment outside Australia
Country [1] 28010 0
Greece
State/province [1] 28010 0
Athens

Funding & Sponsors
Funding source category [1] 321559 0
Commercial sector/Industry
Name [1] 321559 0
Lallemand Health Solutions
Country [1] 321559 0
Canada
Funding source category [2] 321560 0
Commercial sector/Industry
Name [2] 321560 0
Biome Australia Trading Pty Ltd
Country [2] 321560 0
Australia
Primary sponsor type
University
Name
La Trobe University
Address
Country
Australia
Secondary sponsor category [1] 324348 0
None
Name [1] 324348 0
Address [1] 324348 0
Country [1] 324348 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320095 0
La Trobe University Human Ethics Committee
Ethics committee address [1] 320095 0
Ethics committee country [1] 320095 0
Australia
Date submitted for ethics approval [1] 320095 0
02/04/2026
Approval date [1] 320095 0
Ethics approval number [1] 320095 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149410 0
Prof Matthew Cooke
Address 149410 0
Room 213, Health Sciences Building 3, La Trobe University, Bundoora, VIC, 3086
Country 149410 0
Australia
Phone 149410 0
+61 3 9479 2484
Fax 149410 0
Email 149410 0
Contact person for public queries
Name 149411 0
Matthew Cooke
Address 149411 0
Room 213, Health Sciences Building 3, La Trobe University, Bundoora, VIC, 3086
Country 149411 0
Australia
Phone 149411 0
+61 3 9479 2484
Fax 149411 0
Email 149411 0
Contact person for scientific queries
Name 149412 0
Matthew Cooke
Address 149412 0
Room 213, Health Sciences Building 3, La Trobe University, Bundoora, VIC, 3086
Country 149412 0
Australia
Phone 149412 0
+61 3 9479 2484
Fax 149412 0
Email 149412 0

Data sharing statement
Will the study consider sharing individual participant data?
No



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.